Old Web
English
Sign In
Acemap
>
authorDetail
>
Anna Prilenskaya
Anna Prilenskaya
Natalizumab
Multiple sclerosis
Risk management
Intensive care medicine
Discontinuation
1
Papers
5
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (1)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia
2019
PLOS ONE
E.P. Evdoshenko
Alexandra Stepanova
M. V. Shumilina
Maria Davydovskaya
Natalia Khachanova
Nikolay Neofidov
Ivan Kalinin
E V Popova
Ekaterina Dubchenko
Natalia Pozhidaeva
Andrey Volkov
Stella Sivertseva
Anna Prilenskaya
N. A. Malkova
D. S. Korobko
Ilona Vergunova
Sergey Shchur
G. S. Makshakov
Show All
Source
Cite
Save
Citations (5)
1